Harnessing the Power of CAR-T Cells in Hematologic and Solid Tumors

A novel immunotherapy technique called chimeric antigen receptor T-cell (CAR-T) therapy uses a patient’s T cells to target and destroy cancer cells. CAR-T-cell therapy was first created to treat hematologic malignancies; however, it has demonstrated impressive results in treating conditions such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). T cells are genetically modified to express artificial receptors that can identify particular tumor-associated antigens. Advances in CAR-T-cell technology have expanded its use to solid tumors, overcoming obstacles associated with T-cell trafficking, tumor microenvironment immunosuppression, and antigen heterogeneity. The molecular underpinnings of CAR-T-cell therapy, its development, its clinical success in treating hematologic tumors, and the tactics used to increase the effectiveness of solid tumor treatment are all covered in this chapter. The chapter concludes by discussing the future potential of CAR-T-cell therapy, including personalized approaches, novel antigen targets, and next-generation CAR-T-cell technologies, to treat a wide range of malignancies. Important developments include the use of bispecific CARs, immune checkpoint inhibitors, and combination therapies to enhance T-cell persistence and tumor targeting. Additionally, safety concerns, such as cytokine release syndrome (CRS) and neurotoxicity, are addressed, along with ongoing efforts to mitigate these risks.